103 related articles for article (PubMed ID: 21294474)
1. CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.
Tarhini AA; Kirkwood JM
Oncology (Williston Park); 2010 Dec; 24(14):1302, 1304. PubMed ID: 21294474
[No Abstract] [Full Text] [Related]
2. Ipilimumab for advanced melanoma: let's not throw caution to the winds.
Lowe M; Delman KA
Oncology (Williston Park); 2010 Dec; 24(14):1296, 1299. PubMed ID: 21294473
[No Abstract] [Full Text] [Related]
3. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
4. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
6. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
7. Improving the therapeutic benefits of ipilimumab.
Subudhi SK; Callahan MK; Wolchok JD
Oncology (Williston Park); 2010 Dec; 24(14):1288, 1294. PubMed ID: 21294472
[No Abstract] [Full Text] [Related]
8. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
10. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Weber J
Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma.
Mansh M
Yale J Biol Med; 2011 Dec; 84(4):381-9. PubMed ID: 22180676
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
13. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
Ribas A; Hanson DC; Noe DA; Millham R; Guyot DJ; Bernstein SH; Canniff PC; Sharma A; Gomez-Navarro J
Oncologist; 2007 Jul; 12(7):873-83. PubMed ID: 17673618
[TBL] [Abstract][Full Text] [Related]
14. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
Ribas A
Oncologist; 2008; 13 Suppl 4():10-5. PubMed ID: 19001146
[TBL] [Abstract][Full Text] [Related]
15. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
16. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
Robert C; Ghiringhelli F
Oncologist; 2009 Aug; 14(8):848-61. PubMed ID: 19648604
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab for advanced melanoma: a nursing perspective.
Ledezma B
Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
[TBL] [Abstract][Full Text] [Related]
18. Melanoma drug wins US approval.
Ledford H
Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
[No Abstract] [Full Text] [Related]
19. Autoimmune inflammatory myopathy after treatment with ipilimumab.
Hunter G; Voll C; Robinson CA
Can J Neurol Sci; 2009 Jul; 36(4):518-20. PubMed ID: 19650371
[No Abstract] [Full Text] [Related]
20. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
Morse MA
Curr Opin Mol Ther; 2005 Dec; 7(6):588-97. PubMed ID: 16370382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
